138.01

0.10% +0.14

After Hours: 129.00 -9.01 -6.53%

Dexcom Inc (DXCM)

Overview News Price History Option Chain Why DXCM Down? Discussions Forecast Stock Split

Dexcom Inc stock is currently priced at $138.01, with a 24-hour trading volume of 4.14M. It has seen a +0.10% increased in the last 24 hours and a -1.49% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $136.3 pivot point. If it approaches the $140.1 resistance level, significant changes may occur.

Previous Close:

$137.87

Open:

$138.91

24h Volume:

4.14M

Market Cap:

$54.66B

Revenue:

$3.62B

Net Income/Loss:

$541.50M

P/E Ratio:

151.66

EPS:

0.91

Net Cash Flow:

$511.90M

1W Performance:

+2.76%

1M Performance:

-1.49%

6M Performance:

+63.62%

1Y Performance:

+11.33%

1D Range:

$134.39

$139.24

52W Range:

$74.75

$142.00

Dexcom Inc Stock (DXCM) Company Profile

Name

Dexcom Inc

Sector

Healthcare (1197)

Industry

Medical Devices (158)

Phone

858-200-0200

Address

6340 Sequence Drive, San Diego, CA

Employee

2,290

Twitter

@dexcom

Next Earnings Date

2024-05-22

Latest SEC Filings

DXCM's Discussions on Twitter

Dexcom Inc Stock (DXCM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Apr-17-23	Upgrade	Raymond James	Outperform → Strong Buy
Mar-29-23	Initiated	UBS	Buy
Jan-26-23	Initiated	Wolfe Research	Outperform
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-12-22	Initiated	Jefferies	Buy
Jul-15-22	Initiated	Bernstein	Outperform
Mar-02-22	Resumed	BofA Securities	Buy
Feb-03-22	Upgrade	BTIG Research	Neutral → Buy
Jan-19-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-07-22	Upgrade	Guggenheim	Neutral → Buy
Oct-18-21	Downgrade	Guggenheim	Buy → Neutral
Jul-21-21	Resumed	Cowen	Outperform
May-28-21	Upgrade	Wells Fargo	Underweight → Equal Weight
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Overweight
Jan-06-21	Upgrade	UBS	Neutral → Buy
Oct-02-20	Downgrade	Wells Fargo	Equal Weight → Underweight
May-27-20	Reiterated	Piper Sandler	Overweight
May-14-20	Initiated	Wells Fargo	Equal Weight
Mar-05-20	Initiated	Citigroup	Buy
Nov-07-19	Reiterated	Canaccord Genuity	Buy
Nov-07-19	Upgrade	Guggenheim	Neutral → Buy
Oct-23-19	Initiated	Stifel	Buy
Nov-28-18	Initiated	UBS	Neutral
Oct-19-18	Upgrade	Goldman	Sell → Neutral
Sep-12-18	Upgrade	Northland Capital	Under Perform → Market Perform
Aug-02-18	Reiterated	Canaccord Genuity	Buy
Jul-02-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-08-18	Upgrade	JP Morgan	Neutral → Overweight
May-11-18	Initiated	BofA/Merrill	Buy
May-03-18	Reiterated	Canaccord Genuity	Buy
Apr-04-18	Initiated	Goldman	Sell
Apr-04-18	Initiated	Guggenheim	Neutral
Mar-23-18	Upgrade	Robert W. Baird	Neutral → Outperform
Jan-04-18	Downgrade	Northland Capital	Market Perform → Under Perform
Sep-28-17	Reiterated	Wedbush	Outperform

View All

Dexcom Inc Stock (DXCM) Latest News

Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Zacks Investment Research

Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom

Zacks Investment Research

3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback

Zacks Investment Research

Dexcom Inc Stock (DXCM) Financials Data

Dexcom Inc (DXCM) Revenue 2024

DXCM reported a revenue (TTM) of $3.62 billion for the quarter ending December 31, 2023, a +24.49% rise year-over-year.

Dexcom Inc (DXCM) Net Income 2024

DXCM net income (TTM) was $541.50 million for the quarter ending December 31, 2023, a +58.70% increase year-over-year.

Dexcom Inc (DXCM) Cash Flow 2024

DXCM recorded a free cash flow (TTM) of $511.90 million for the quarter ending December 31, 2023, a +68.00% increase year-over-year.

Dexcom Inc (DXCM) Earnings per Share 2024

DXCM earnings per share (TTM) was $1.31 for the quarter ending December 31, 2023, a +61.73% growth year-over-year.

Dexcom Inc Stock (DXCM) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Dolan Matthew Vincent	EVP Strategy and Corporate Dev	Apr 15 '24	Sale	137.81	1,990	274,242	42,377
SAYER KEVIN R	President CEO and Chairman	Apr 08 '24	Sale	138.30	49,633	6,864,136	283,893
Brown Michael Jon	EVP Chief Legal Officer	Mar 28 '24	Sale	140.04	2,624	367,472	68,682
Stern Sadie	EVP Chief Human Resources	Mar 25 '24	Sale	140.00	4,137	579,180	76,304
Dolan Matthew Vincent	EVP Strategy & Corp Dev	Mar 15 '24	Sale	130.21	4,203	547,259	44,367
SAYER KEVIN R	President CEO and Chairman	Mar 12 '24	Sale	133.36	81,007	10,802,803	333,526
Stern Sadie	EVP Chief Human Resources	Mar 12 '24	Sale	133.61	20,321	2,715,006	80,441
Leach Jacob Steven	EVP Chief Operating Officer	Mar 12 '24	Sale	134.41	14,639	1,967,638	273,913
Sylvain Jereme M	EVP Chief Financial Officer	Mar 12 '24	Sale	134.41	11,661	1,567,363	85,534
Brown Michael Jon	EVP Chief Legal Officer	Mar 12 '24	Sale	134.41	8,799	1,182,680	71,306

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.